Australian Suicide Prevention using Health-Linked Data (ASHLi) : protocol for a population-based case series study by Chitty, Kate M. et al.
1Chitty KM, et al. BMJ Open 2020;10:e038181. doi:10.1136/bmjopen-2020-038181
Open access 
Australian Suicide Prevention using 
Health- Linked Data (ASHLi): Protocol 
for a population- based case series study
Kate M Chitty,1 Jennifer L Schumann,2 Andrea Schaffer   ,3 Rose Cairns   ,4,5 
Nicole J Gonzaga   ,1 Jacques E Raubenheimer,1 Gregory Carter,6 Andrew Page,7 
Sallie- Anne Pearson,3 Nicholas A Buckley1
To cite: Chitty KM, 
Schumann JL, Schaffer A, 
et al.  Australian Suicide 
Prevention using Health- 
Linked Data (ASHLi): Protocol 
for a population- based case 
series study. BMJ Open 
2020;10:e038181. doi:10.1136/
bmjopen-2020-038181
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2020- 
038181).
Received 10 March 2020
Revised 09 April 2020
Accepted 14 April 2020
For numbered affiliations see 
end of article.
Correspondence to
Dr Kate M Chitty;  
 kate. chitty@ sydney. edu. au
Protocol
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Introduction In Australia, suicide is the leading cause of 
death for people aged 15–44 years. Health professionals 
deliver most of our key suicide prevention strategies via 
health services, but other efficacious population- level 
strategies include means restriction and public awareness 
campaigns. Currently, we have no population- level data 
allowing us to determine which individuals, in what 
parts of Australia, are likely to use our most promising 
interventions delivered by health services. The aims of this 
study are to describe: (1) health service utilisation rates in 
the year prior to death by suicide, and how this varies by 
individual case characteristics; (2) prescribed medicines 
use in the year prior to death by suicide, medicines used in 
suicide by poisoning and how this varies by individual case 
characteristics.
Methods and analysis This is a population- based case 
series study of all suicide cases in Australia identified 
through the National Coronial Information System (NCIS) 
from 2013 to 2019. Cases will be linked to administrative 
claims data detailing health service use and medicines 
dispensed in the year before death. We will also obtain 
findings from the coronial enquiry, including toxicology. 
Descriptive statistics will be produced to characterise 
health service and prescribed medicine use and how 
utilisation varies by age, sex, method of death and 
socioeconomic status. We will explore the geographical 
variability of health service and medicine use, 
highlighting regions in Australia associated with more 
limited access.
Ethics and dissemination This project involves the use 
of sensitive and confidential data. Data will be linked 
using a third- party privacy- preserving protocol meaning 
that investigators will not have access to identifiable 
information once the data have been linked. Statistical 
analyses will be carried out in a secure environment. 
This study has been approved by the following ethics 
committees: (1) the Justice Department Human Research 
Ethics Committee (REF: CF/17/23250), (2) the Western 
Australian Coroners Court (REF: EC 14/18 M0400), (3) 
the Australian Institute of Health and Welfare (REF: 
EO2017/4/366) and (4) NSW Population & Health Services 
Research Ethics Committee (REF: 2017/HRE1204). 
Findings will be published in peer- reviewed journals, 
presented at conferences and communicated to regulatory 
authorities, clinicians and policy- makers.
IntroduCtIon
background
Suicide prevention is a worldwide public 
health priority.1 In Australia, suicide is the 
leading cause of years of potential life lost, 
the leading cause of death for people aged 
between 15 and 44 years, and suicide rates 
have remained largely unchanged over the 
past decade.2
The most effective suicide prevention strat-
egies delivered by health services in Australia 
include training general practitioners (GPs) 
to identify and support people in distress, 
similar training for other health personnel 
who are likely to encounter individuals at 
risk (‘gatekeepers’) and implementation of 
psychosocial treatments.3 However, we do not 
have robust estimates of the proportion of 
people who will visit a GP, have contact with 
gatekeepers or receive psychosocial treat-
ments before they die from suicide. In order 
to best estimate the scope of these promising 
interventions and, accordingly, reinforce or 
redirect our efforts, we need to know what 
health services were, and were not, utilised 
by people in Australia in the period prior to 
suicide.
strengths and limitations of this study
 ► This is a population- based case series study of all 
suicide cases in Australia from 2013 to 2019.
 ► Coronial data will be linked to individual dispensing 
records for prescribed medicines to create a com-
prehensive view of medicine access at the time of 
death.
 ► By measuring the geographical variability of health 
service use across the cohort, we will highlight re-
gions in Australia with reduced access to these im-
portant avenues for suicide prevention.
 ► All cases in the study have died from suicide, there-
fore, the risk of suicide cannot be established. copyright.
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Psychotropic medicines have complex modifying 
effects on the risk of suicide, which may change substan-
tially with age, indication, agent and duration.4 These 
medicines are also some of the most common substances 
used in suicide by poisoning.5 Currently, however, we 
do not know what medicines have been prescribed to 
people who die of suicide, and what proportion use their 
prescribed medicines for self- poisoning. This is the key 
information for prescribers and could influence future 
means restriction activities.
The Australian Suicide Prevention using Health- Linked 
Data (ASHLi) project is a population- based case series 
study. The overarching aims are to describe and charac-
terise the following for all suicides in Australia between 
2013 and 2019:
(1) health service utilisation rates (both general and 
mental health) in the year prior to death by suicide, and 
how this varies by individual case characteristics; and (2) 
prescribed medicines use in the year prior to death by 
suicide, medicines used in suicide by poisoning and how 
this varies by individual case characteristics.
summary of the existing literature
Healthcare utilisation prior to suicide using administrative claims 
data
The most recent review of healthcare utilisation prior to 
suicide6 incorporated 13 population- based studies using 
administrative claims and mortality data from six jurisdic-
tions (USA, Denmark, Taiwan, Republic of Korea, Canada 
and Sweden). The study found that contact with primary 
healthcare professionals in the month before suicide 
ranged between 50% (USA between 2000 and 2010) and 
73% (Taiwan, 2006 and Canada, 1992–2000). In the 12 
months preceding suicide, contact with a primary health 
professional ranged between 80% (Taiwan, 2001–2004) 
and 92% (Canada, 1998–2011). The ranges were consid-
erably lower when the focus was on mental health contacts 
alone: from 7% (Sweden, 1991–2003) to 30% (Canada, 
1998–2011) in the month before suicide. In the 12 months 
prior to death, mental health contact ranged from 21% 
(UK, 1996–2005) to 25% (Sweden, 1991–2003). There-
fore, estimates of healthcare contact prior to suicide are 
highly variable, which may be partly due to differences in 
healthcare systems, study methodology and data quality. 
Importantly, there are pronounced within- country differ-
ences in healthcare contact based on characteristics such 
as sex, age6 and race/ethnicity.7 8
Medicine use prior to suicide using administrative claims data and 
toxicology findings at the time of death
Most analyses of medicine- linked data have been 
population- based cohort studies focused on examining 
suicide risk among all users of individual drug classes 
within a population. We identified only one retrospec-
tive study linking coroner records with person- level 
dispensing data.9 This Northern Ireland study investi-
gated the odds of suicide associated with prescription of 
mental health and pain medicines, compared with living 
controls from the general population. The use of both 
mental health and pain medicines was associated with 
higher odds of suicide.10 11 This study also uncovered 
that recent prescription of these medicines (ie, in the 3 
months preceding death) was associated with the highest 
risk of suicide, showing that pharmaceutical claims may 
have the ability to identify the emergence of mental 
health symptoms in the lead up to suicide.
Other information about prior medicine use in people 
who have died from suicide comes from toxicology 
studies that investigate medicines detected at autopsy. 
A study investigating the relative toxicity of a number of 
antidepressant medicines used in overdose reported wide 
differences in toxicity between classes and recommended 
caution in prescribing particular medicines to high- 
risk patients.12 A Canadian study reported that opioids, 
sedatives, tricyclic antidepressants and over- the- counter 
medicines were the most frequent substances detected 
in overdose from coroner’s toxicology reports, again 
with authors advising caution in prescribing and careful 
follow- up.5
Autopsy studies to date have yielded important infor-
mation for means restriction and clinical practice, yet 
interpreting medicine utilisation in autopsy- based anal-
yses is subject to numerous limitations—it is unknown: 
(1) what medicines detected at autopsy were prescribed 
to the individual; or (2) whether medicines not detected 
are because the individual was not prescribed the medi-
cine; prescribed the medicine but not adherent at the 
time of death; the samples collected were insufficient 
for toxicological analysis; or analyses conducted did not 
have the range or sensitivity to detect all therapeutic drug 
concentrations.
Healthcare and medicine use in the general Australian population
In Australia, a wide range of health services are subsidised 
through the Medicare Benefits Scheme (MBS). Under the 
MBS, all Australian citizens and residents receive subsi-
dised healthcare for out- of- hospital medical services and 
are guaranteed free treatment in public hospitals. Using 
the MBS, the Australian Institute of Health and Welfare 
(AIHW) reported that 88% of the Australian popula-
tion visited a GP in 2017–2018, but that the rate of use 
varied considerably depending on where people lived.13 
Data show that people living in remote areas have poorer 
access to, and the use of, health services compared with 
people living in major cities.14 In terms of mental health 
treatment, about 10% of the population received MBS- 
subsidised services in 2017–2018; this rate was higher in 
women (12.2%) than men (8.3%) and people aged 35–44 
years accessed mental health services the most (13.8% of 
people in this age group).15
The Pharmaceutical Benefits Scheme (PBS) was estab-
lished to subsidise a wide range of prescription medicines 
for all Australian citizens and residents. Using the PBS 
data collection, the AIHW determined that 16.8% of the 
Australian population received prescriptions for mental 
health related medicines in 2017–2018. Women had a 
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Table 1 Number of suicide cases meeting study inclusion 
criteria per year, as identified by the NCIS access liaison 
officer
Year of death
Cases to be 
linked (n)—
Australia
Cases to 
be linked 
(n)—NSW
Percentage 
of all NCIS 
cases closed 
by coroner*
2013† 1272 317 96.5
2014 2760 753 95.0
2015 2893 760 93.0
2016 2693 692 92.9
2017 2823 829 75.6
2018 1813 585 50.8
2019 285 128 19.9
Total 14 639 4064
*At the time of data extraction .
†Only cases after 1 July 2013 were used.
NCIS, National Coronial Information System; NSW, New South 
Wales.
higher proportion of mental health related prescriptions 
compared with men (20% vs 13.6%). Antidepressants were 
the most common mental health medicine prescribed, 
followed by anxiolytics, sedatives and antipsychotics.15
MEthods And AnAlysIs
design
ASHLi is a population- based case series study, which 
will detail the health service and medicine history of all 
suicides identified through the National Coronial Infor-
mation System (NCIS) that occurred in Australian resi-
dents on/after 1 July 2013. All suicides will be linked to 
health service and medicine use that occurred in the year 
prior to death.
Case definition
The cases in our study are all deaths recorded by the NCIS 
as intentional or undetermined intent that occurred on/
after 1 July 2013 until the 10 October 2019 (date of data 
extraction) across all Australian jurisdictions according to 
the following inclusion criteria:
 ► Case closed by the coroner at the time of data 
extraction.
 ► Manner of death determined by the coroner to be 
intentional self- harm or undetermined intent.
The number of cases for each year are presented in 
table 1.
Cases will also be confirmed using information from the 
National Death Index (NDI). Any suicide cases from the 
NCIS that are not coded as suicide in the NDI will still be 
treated as a case; however, the level of agreement between 
the two data sources will be reported. Only cases that are 
successfully linked to their PBS/MBS (for all cases) and 
New South Wales (NSW) Health records (for NSW cases) 
will be included in further analyses.
data sources
Table 2 lists all the datasets that will be linked in ASHLi.
Coronial data
The National Coronial Information System (NCIS) 
captures Australia’s coronial information for all deaths 
notified to a coroner since 2000, it is managed by the 
Victorian Department of Justice and Community Safety. 
All deaths that are intentional, accidental or of unde-
termined intent are reviewed by a coroner and hence 
suicides are well captured. The NCIS carries detailed 
information, including demographics, autopsy and toxi-
cology findings and details surrounding death (including 
method of death). Cases for which suicide is not a clear 
cause of death can be supported with information from 
the National Death Index (NDI), a national dataset of all 
causes of death held by the AIHW.
Australia-wide administrative data
Australia maintains a publicly funded, universal health-
care system entitling all citizens and permanent residents 
to subsidised medicines through the PBS. The PBS reim-
burses community pharmacies and private hospitals for 
PBS- listed medicines.16 The PBS data capture approxi-
mately 93% of prescription medicine use in Australia.17 
The PBS does not subsidise medicines sold over the 
counter, complementary and alternative medicines, 
private prescriptions, medicines dispensed within public 
hospitals to inpatients or opioid maintenance treatments 
(methadone and buprenorphine) and, therefore, these 
medicines do not appear in the PBS collection. The MBS 
is Australia’s government- funded healthcare subsidies 
scheme. The scheme subsidises a wide range of both 
public and private medical services including consulta-
tion fees for doctors and specialists, clinical psychology, 
diagnostic tests and examinations and most surgical and 
therapeutic procedures.
NSW administrative data
The NSW Emergency Department Data Collection 
(EDDC) collects data on presentations to emergency 
departments of public hospitals in NSW. The NSW 
Admitted Patient Data Collection (APDC) records all inpa-
tient separations (discharges, transfers and deaths) from 
all public, private, psychiatric and repatriation hospitals 
in NSW, as well as public multipurpose services, private 
day procedure centres and public nursing homes. The 
NSW Mental Health Ambulatory Data Collection (MH- 
AMB) includes information in relation to mental health 
day programmes, psychiatric outpatients and outreach 
services (eg, home visits). It also includes information 
regarding care provided by hospital- based consultation- 
liaison services to admitted patients in non- psychiatric 
and hospital emergency settings and care provided by 
community workers and clients in staffed community resi-
dential settings, mental health promotion and prevention 
services.
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Table 2 Data sources to be linked in ASHLi
Data set Data description Data provider
Geographical 
coverage
Coverage in 
years
Coronial cases 
and information
The National Coronial Information System (NCIS) 
is a national repository containing data on deaths 
reported to a coroner in Australia and New Zealand.
NCIS Australia- wide 1 July 2013–10 
October 2019
Medicines 
dispensing 
claims
Australia’s Pharmaceutical Benefits Scheme (PBS) is 
a national drug subsidy programme for the approved 
prescription medication and captures the dispensing 
of all PBS- approved medicines in Australia.
Data will be extracted for each individual during the 
exposure period.
AIHW Australia- wide 1 July 2012–
latest available 
before death
Health service 
records
The Medicare Benefits Scheme (MBS) is a listing of 
the Medicare services subsidised by the Australian 
government including any healthcare contacts, and 
any items used that are listed under the Mental 
Health Plan.
AIHW Australia- wide 1 July 2012–
latest available 
before death
Death records The NDI is a database developed and maintained by 
the AIHW. The database is a listing of all deaths that 
have occurred in Australia since 1980.
AIHW Australia- wide 1 July 2013–
latest available
Admitted patient 
data
The Admitted Patient Data Collection (APDC) 
contains records of all inpatient separations 
(discharges, transfers and deaths) from all public, 
private, psychiatric and repatriation hospitals in 
NSW.
NSW Health 
APDC
NSW 1 July 2012–
latest available
Ambulatory 
mental health 
data
The Mental Health Ambulatory (MH- AMB) Data 
Collection is dedicated to the assessment, 
treatment, rehabilitation or care of non- admitted 
patients. It may include mental health day 
programmes, psychiatric outpatients and outreach 
services (eg, home visits). The data record ‘contacts’ 
(as opposed to ‘episodes of care’) by clinicians to a 
patient.
NSW Health 
MH- AMB data 
collection
NSW 1 July 2012–
latest available
Emergency 
department data
The Emergency Department Data Collection (EDDC) 
provides information about patient presentations to 
the emergency departments of public hospitals in 
NSW. By 2016, the EDDC captured 100% of public 
hospitals in NSW, prior to this time, the number of 
contributing hospitals steadily increased from 90 to 
150 in 2010.
NSW Health 
EDDC
NSW 1 July 2012–
latest available
AIHW, Australian Institute of Health and Welfare; APDC, Admitted Patient Data Collection 
; ASHLi, Australian Suicide Prevention using Health- Linked Data ; EDDC, Emergency Department Data Collection; MH- AMB, Mental Health 
Ambulatory; NCIS, National Coronial Information System 
; NDI, National Death Index; NSW, New South Wales; PBS, Pharmaceutical Benefits Scheme.
Measurements
Data from coroner reports
The information from the NCIS that will be extracted 
for each suicide is listed in table 3. Data extraction 
from the toxicology, police and autopsy reports will be 
completed by research assistants and students. Study 
investigators (KC, RC and JS) will provide training in the 
data extraction processes and will be available to address 
any questions and reach consensus regarding coding for 
more complex cases.
Data from the PBS and MBS
The data from the PBS that will be linked to each case 
include the date the medicine was prescribed and date the 
medicine was dispensed, medicine name, form, strength, 
number of prescriptions dispensed, and specialty of the 
prescriber. The data from the MBS that will be linked 
to each case include the date and type of health service 
accessed.
Data from the APDC, EDDC and MH-AMB
Data from the APDC and EDDC that will be linked to each 
case include dates of episodes of care, diagnosis codes 
associated with an episode of care, and mode of arrival 
and separation. Additionally, the triage category assigned 
to ED visits will be linked. Data from the MH- AMB that 
will be linked to each case include dates associated with 
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Table 3 Information collected from the NCIS for each included suicide case
Variable(s) Description
Deidentified 
demographic 
variables
Year of death, age at the time of death, sex, marital status, employment status, country of birth, years in 
the country
ICD-10 – cause of 
death
As determined during the Australian Bureau of Statistics mortality coding process
Medical cause of 
death
As determined by the coroner
Incident date and 
time
When the incident that caused death occurred
Mechanism and 
object of injury
Mechanism by which death occurred/objects involved in the death
Geocoding result Statistical areas 3 and 4 of residential address at the time of death. Statistical areas are provided by the 
Australian Statistical Geography Standard for use by the Australian Bureau of Statistics and others to 
analyse spatially integrated information
Toxicology report We will document all drugs listed in each report, including their concentrations, the sample sites 
analysed, level of decomposition of the body and any other limitations to the toxicological testing.
each contact, mental health diagnoses associated with 
contact and type of service.
data linkage
The data linkage in this study will adhere to the separa-
tion principle for data linkage. Identifying information is 
supplied to the data linkage staff by the NCIS data custo-
dians. Once the relevant linkage processes have been 
performed, deidentified data will then be available to 
researchers for analyses.
The separation principle will be maintained throughout 
the data linkage process as follows:
1. The researchers will not have access to identifying in-
formation once they have received the linked data.
2. Only approved research personnel will have access to 
the linked data and perform data analysis.
Planned data analysis
Aim 1: to describe health service utilisation rates 
(both general and mental health) in the year prior to 
death by suicide and how this varies by individual case 
characteristics.
Using descriptive statistics, we will comprehensively 
describe and characterise the healthcare utilisation in 
the cases within our sample in the year preceding suicide 
death by using tMBS data supplied by AIHW. Additionally, 
healthcare utilisation for the NSW cases will be described 
and categorised using the NSW Health data. Categorical 
data will be described using frequencies and percentages.
Generalised linear models will be used to determine 
predictors of healthcare contacts before death. The 
dependent healthcare utilisation variables we will inves-
tigate include ambulatory mental health contact, acute 
mental health contact and no mental health contact. 
Independent variables and covariates examined will 
include: age, sex, socioeconomic status (SES) and class of 
medicine prescribed. ORs with 95% CIs will be reported 
for each predictor.
Spatial maps of age and sex standardised suicide rate 
according to the presence or absence of healthcare 
within a month of death will be generated for Australia 
using statistical area 3 (SA3) regions of residence at the 
time of death.
Aim 2: to describe prescribed medicines use in the 
year prior to death by suicide, medicines used in suicide 
by poisoning and how this varies by individual case 
characteristics.
Using descriptive statistics, we will comprehensively 
describe and characterise the dispensed prescription 
medication use in our sample in the year preceding 
suicide death using the PBS data supplied by AIHW. 
Categorical data will be described using frequencies and 
percentages.
For the prescription medicines that are not used to 
treat mental illness, such as antibiotics, ACE inhibitors, 
gabapentinoids or isotretinoin, we will conduct dispro-
portionality analysis18 to determine whether the rate of 
use in suicide cases is above that reported in the Austra-
lian population using other available sources of national 
representative PBS dispensing data.
Generalised linear models will be used to determine 
the predictors of prescribed medicine use patterns 
including: cases not dispensed a psychotropic medicine, 
cases non- compliant with psychotropic medicine at the 
time of death, initiation of psychotropic medicine within 
1 month of death and discontinuation of psychotropic 
medicine within 1 month of death. Independent vari-
ables and covariates examined will include age, sex, SES, 
method of death and class of medicine prescribed. ORs 
with 95% CIs will be reported for each predictor.
Spatial maps of suicide according to the presence or 
absence of medicine within a month of death will be 
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generated for Australia using SA3 regions of residence at 
the time of death.
Patient and public involvement statement
There were no funds or time allocated for the patient 
and public involvement, so we were unable to involve the 
public in the design of the study. However, we will develop 
a representative public committee to help us develop our 
dissemination strategy to mental health advocacy groups 
and the community.
EthICs And dIssEMInAtIon
This project involves the use of sensitive and confiden-
tial data. Data will be linked using a third- party privacy- 
preserving protocol meaning that investigators will not 
have access to identifiable information once the data 
have been linked. Statistical analyses will be carried out 
in a secure environment. ASHLi has been approved by 
the following data custodians and ethics committees: (1) 
the National Coronial Information System (NCIS) (REF: 
M0400), (2) the Justice Department Human Research 
Ethics Committee (REF: CF/17/23250), (3) the Western 
Australian Coroners Court (REF: EC 14/18 M0400); (4) 
the Australian Institute of Health and Welfare (REF: 
EO2017/4/366), (5) the Department of Health and 
(6) NSW Population & Health Services Research Ethics 
Committee (REF:2017/HRE1204). Findings will be 
published in peer- reviewed journals, presented at confer-
ences and communicated to regulatory authorities, clini-
cians, mental health advocacy groups and policy- makers.
dIsCussIon
Australia is one of the few countries in the world with an 
investment in data linkage infrastructure to allow a project 
of this scope to be achieved. This study will significantly 
advance knowledge of health service and medicine utili-
sation prior to suicide in Australia. The project outcomes 
will have a significant impact on suicide prevention initia-
tives by identifying gaps in our national suicide preven-
tion strategy, and subsequently providing information on 
ways to optimise future approaches.
ASHLi will result in the following central outcomes.
Identifying the reach of suicide prevention initiatives delivered 
via health services
By identifying population characteristics associated with 
different types of health service use, this analysis will 
provide important information for targeting suicide 
initiatives. For example, if one type of service is used 
more commonly in younger female individuals then rein-
forcing tailored programmes toward this group within 
that service may increase the efficacy of suicide preven-
tion compared with broadly focused interventions. 
Furthermore, locating where high/low service use occurs 
and determining when, in relation to suicide, particular 
services are most commonly accessed, the analysis will 
provide specific information about where and when to 
reinforce or redirect our current strategies.
highlighting barriers to health service utilisation
By interpreting health service use in concert with health 
service location we will shed light on whether barriers 
to health service utilisation may be due to intrinsic 
factors (unwillingness by the individual to seek help) 
versus extrinsic factors (remoteness/lack of services). 
The former will highlight groups of people for whom 
non- clinical forms of intervention may be the most effi-
cacious and where they should be targeted (ie, online 
therapy, restricting means of suicide and public health 
campaigns).
Providing information to help target means restriction
Means restriction is the primary mode of suicide preven-
tion applicable to those who do not access health services. 
Our analysis of the methods of suicide that are most 
commonly used in these people will provide information 
on priority suicide methods to target, in what populations 
and where.
highlighting potentially harmful medicine use
Information on medicines used in overdose will have 
important implications for regulatory authorities and 
prescribers, especially when psychotropic medicine use 
occurs in the absence of mental health service utilisa-
tion, which is against best practice recommendations. 
We will also provide further evidence regarding concerns 
about the prosuicidal effects of several non- psychotropic 
medicines.
Foundational research for future studies
The rich data source created in order to achieve the aims 
of the current proposal will be used for many further 
analyses by the study team. For example, with the addi-
tion of appropriate data from the general population, 
we can zoom in on particular medicine classes of interest 
and conduct disproportionality analysis to assess how the 
use of medicines by our sample differs compared with the 
general population.
limitations
There are a number of limitations associated with the 
nature of the data used in this study. First, there will be an 
under- ascertaininment of health service use for the cases 
in our study. MBS data do not include enough detail on 
mental health services provided in the hospital to allow 
the identification of hospitalised self- harm and other 
emergency psychiatric presentations. Health service data 
collected by State governments include detailed data on 
hospitalisations and non- hospital mental health services, 
therefore is not constrained by the same limitations. 
Therefore, we will supplement the MBS mental health 
data using NSW state data collections. Initially, we have 
chosen to use this approach in NSW given its large popula-
tion (around one third of Australians). By comparing the 
estimates we receive from MBS alone to MBS plus NSW 
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state collections, we will be able to estimate the degree 
of under- ascertainiment in other states in Australia and 
report on this accordingly.
Medicine use will also be limited by under- ascertainment. 
It is possible to obtain scripts outside the PBS, such as 
private prescriptions, medicines dispensed within public 
hospitals to inpatients or opioid maintenance treatments 
(methadone and buprenorphine) will not be captured. 
The study will also not capture medicines sold over the 
counter, complementary or alternative medicines.
Another limitation is that all cases in the study have died 
from suicide, therefore, the risk of suicide associated with 
any healthcare or medicine use patterns cannot be estab-
lished. This study will instead highlight these patterns, so 
that further studies with appropriate control groups can 
be established.
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